Document is current
Any future updates will be listed below
-
Authors
Daniels, Alisha J.
McDade, Eric
Llibre-Guerra, Jorge J.
Xiong, Chengjie
Perrin, Richard J.
Ibanez, Laura
Supnet-Bell, Charlene
Cruchaga, Carlos
Goate, Alison
Renton, Alan E.
Benzinger, Tammie L. S.
Gordon, Brian A.
Hassenstab, Jason
Karch, Celeste
Levey, Allan
Morris, John C.
Buckles, Virginia
Allegri, Ricardo F.
Chrem, Patricio
Berman, Sarah B.
Chhatwal, Jasmeer P.
Farlow, Martin R.
Fox, Nick C.
Day, Gregory S.
Ikeuchi, Takeshi
Jucker, Mathias
Levin, Johannes
Lee, Jae-Hong
Aguillon, David
Takada, Leonel
Sosa, Ana Luisa
Martins, Ralph
Mori, Hiroshi
Noble, James M.
Salloway, Stephen
Huey, Edward
Sánchez-Valle, Raquel
Schofield, Peter R.
Roh, Jee Hoon
Bateman, Randall J.
,
Benzinger, Tammie L. S.
Holtzman, David M.
Fagan, Anne M.
Franklin, Erin
Xu, Xiong
Lu, Ruijin
Wang, Guoqiao
Li, Yan
Gremminger, Emily
Courtney, Laura
Jerome, Gina
Herries, Elizabeth
Stauber, Jennifer
Baker, Bryce
Minton, Matthew
Picarello, Danielle M.
Hornbeck, Russ
Chen, Allison
Chen, Charles
Flores, Shaney
Joseph-Mathurin, Nelly
Jarman, Steve
Jackson, Kelley
Keefe, Sarah
Koudelis, Deborah
Massoumzadeh, Parinaz
McCullough, Austin
McKay, Nicole
Nicklaus, Joyce
Pulizos, Christine
Wang, Qing
Sabaredzovic, Edita
Smith, Hunter
Scott, Jalen
Simmons, Ashlee
Rizzo, Jacqueline
Sullivan, Jennifer
Stout, Sarah
Aschenbrenner, Andrew J.
Marsh, Jacob
Barthelemy, Nicolas
Xu, Jinbin
Johnson, Erik C. B.
Seyfried, Nicholas T.
Surace, Ezequiel
Vazquez, Silvia
Ikonomovic, Snezana
Nadkarni, Neelesh K.
Cash, David M.
Ryan, Natalie S.
Graff-Radford, Neill R.
Kasuga, Kensaku
Laske, Christoph
Hofmann, Anna
Kuder-Buletta, Elke
Graber-Sultan, Susanne
Obermueller, Ulrike
Roedenbeck, Yvonne
Voglein, Jonathan
Lopera, Francisco
Milena, Yudy
Ramirez, Laura
Brooks, William S.
Bechara, Jacob A.
Niimi, Yoshiki
Rosa-Neto, Pedro
Ringman, John
Masters, Colin
-
Funding
Funding for this research was provided by:
Alzheimer's Association (SG-20-690363-DIAN)
Raul Carrea Institute for Neurological Research
Research and Development Grants for Dementia from Japan Agency for Medical Research and Development (JP23dk0207066)
Research and Development Grants for Dementia from Japan Agency for Medical Research and Development (JP23dk0207066)
German Center for Neurodegenerative Diseases
Korea Health Technology R&D Project through the Korea Health Industry Development Institute
Korea Dementia Research Center
Ministry of Health Office for Healthcare Transformation (HI21C0066)
Spanish Institute of Health Carlos III
National Institute on Aging (U19AG032438)
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 13 November 2025
First Online: 16 February 2026
Competing interests
: RJB, Professor of Neurology at Washington University’s School of Medicine (WUSM) receives lab research funding from the National Institutes of Health, Alzheimer’s Association, BrightFocus Foundation, Rainwater Foundation, Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Tau Consortium, Novartis, Centene Corporation, Association for Frontotemporal Degeneration, the Cure Alzheimer’s Fund, Coins for Alzheimer’s Research Trust Fund, The Foundation for Barnes-Jewish Hospital, Good Ventures Foundation, DIAN-TU Pharma Consortium, Centene Corporation, Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and Company and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffman La Roche, and an anonymous organization). RJB has received honoraria as a speaker/consultant/advisory board member from Eisai, F. Hoffman-LaRoche, Janssen, Biogen; and reimbursement of travel expenses from Korean Dementia Association, American Neurological Association, Fondazione Prada, Weill Cornell Medical College, Harvard University, CTAD, FBRI, Beeson Foundation, Adler, Alzheimer’s Association Roundtable, Duke Margolis Roundtable, Bright Focus Foundation, Tau Consortium Investigator’s, NAPA Advisory Council on Alzheimer’s Research. RJB serves as principal investigator of the DIAN-TU, which is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium (Active: Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, F. Hoffman-La Roche/Genentech, and Janssen. Previous: Abbvie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, and United Neuroscience). The DIAN-TU-001 Clinical Trial is supported by Pharmaceutical Partners Eli Lilly and Company, F. Hoffman-La Roche and Janssen, the Alzheimer’s Association, NIH U01AG042791, NIH U01AG42791-S1 (FNIH and Accelerating Medicines Partnership), NIH R01AG046179, NIH R56AG053267, NIH R01AG053267, NIH U01AG059798, NIH R01AG068319, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState, Cerveau, Signant Health and Eisai Corporation. RJB is a co-founder of C2N Diagnostics and receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University (WU) has equity ownership interest in C2N Diagnostics. C2N Diagnostics will be analyzing samples from the Knight Family DIAN-TU-001 trial of E2814 for primary, secondary, and exploratory endpoints. Should the DIAN-TU trials impact the value of C2N Diagnostics, WU and RJB could directly benefit. TLSB has received funding from the National Institutes of Health and Siemens; has a licensing agreement from Sora Neuroscience but receives no financial compensation; has received honoraria for lectures, presentations, speakers bureaus, or educational events from Biogen and Eisai Genetech; has served on a scientific advisory board for Biogen; holds a leadership role in other board, society, committee, or advocacy groups for the American Society for Neuroradiology (unpaid) and Quantitative Imaging Biomarkers Alliance (unpaid); and has participated in radiopharmaceuticals and technology transfers with Avid Radiopharmaceuticals, Cerveau, and LMI. JPC serves as the chair of the American Neurological Association Dementia and Aging Special Interest Group and is on the medical advisory board of Humana Healthcare. CC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Dr. Cruchaga is a member of the advisory board of Vivid genetics, Halia Therapeutics Adx Healthcare and ADMit. JH is a paid consultant for F. Hoffmann-La Roche, Ltd., Takeda, and Lundbeck, and is on the Data Safety and Monitoring Board for Eisai. JJLG is supported by NIH-NIA (K01AG073526), the Alzheimer’s Association (AARFD-21-851415, SG-20-690363), the Michael J. Fox Foundation (MJFF-020770), the Foundation for Barnes-Jewish Hospital and the McDonnell Academy. EMD received support from the National Institute on Aging, an anonymous organization, the GHR Foundation, the DIAN-TU Pharma Consortium, Eli Lilly, and F Hoffmann La-Roche; has received speaking fees from Eisai and Eli Lilly; and is on the data safety and monitoring board and advisory boards of Eli Lilly, Alector, and Alzamend. JCM is the Friedman Distinguished Professor of Neurology, Director, Knight ADRC; Associate Director of DIAN and Founding Principal Investigator of DIAN. He is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. RJP receives research funding from the National Institutes of Health and the National Institute on Aging. AER has received funding from National Institute on Aging, National Institute of Neurological Disorders and Stroke, Alzheimer’s Association, JPB Foundation, and Donors Cure. AG serves on the scientific review board for Genentech and the scientific advisory board Muna Therapeutics. PRS receives funding from the National Health and Medical Research Council (Australia) grants 1176716 and 2022057 and the Medical Research Future Fund (Australia) grants 1200428 and 1200428. He is a director (unpaid) of the Australian Dementia Network Ltd. NCF reports consulting fees from Biogen, Eisai, Ionis, Lilly, Roche/Genentech, and Siemens – paid to UCL; he has served on a Data Safety Monitoring Board for Biogen; he acknowledges grant support from the Alzheimer’s Society, Alzheimer’s Research UK, Rosetrees Trust, the Sigrid Rausing Trust, the UK Dementia Research Institute and the UK NIHR UCLH Biomedical Research Centre. All other authors have no competing interests to disclose. CK is an associate editor of npj Dementia.
